Estrogen Hormone Products

Evaluating Quality Performance of Extemporaneously Compounded Estrogen Hormone Products

The purpose is to determine if the two estradiol products can deliver similar amounts of estradiol after single and multiple dosing.

Study Overview

• Status: Recruiting
• Conditions: Menopause
• Intervention / Treatment: Drug: Estrogel 0.06 % Topical Gel; Drug: Compounded estradiol gel

• Study Type: Interventional
• Enrollment (Estimated): 12
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Audra Stinchcomb, PhD; Phone Number: 410-706-2646; Email: astinchc@rx.umaryland.edu

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • Recruiting
      • General Clinical Research Center (GCRC) at the University of Maryland Medical Center
      • Contact: Bianca Reginauld
      • Principal Investigator: Audra Stinchcomb, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Postmenopausal women, who are of any ethnic background, between the age of 45 to 65 years old
2. Provide written informed consent before initiation of any of the study procedures
3. Able to adhere to the study restrictions and study schedule
4. Volunteer has mid thighs of at least 42 cm (16.5 in) in circumference to accommodate the products to be tested at an area of 400 cm2 per thigh
5. Volunteer has legs that measure ≥46 cm (18.1 in) in length from the iliac crest to the top of the patella or large enough to accommodate the products to be tested at an area of 400 cm2 per thigh with the subject being comfortable with the template placement
6. Volunteer deemed to be healthy as judged by the Medically Accountable Investigator (MAI) and determined by medical history, physical examination, and medication history
7. Negative urine drug screening test (cannabinoids, amphetamines, barbiturates, benzodiazepine, cocaine, methadone, opiates, PCP)
8. Have normal screening laboratories for white blood cells (WBC), hemoglobin (Hgb), platelets, sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, alanine transaminase (ALT), and aspartate aminotransferase (AST)
9. Have normal screening laboratories for urine protein and urine glucose
10. Naturally postmenopausal (absence of periods for ≥ 1 year or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy (menopause induced by removal of ovaries)
11. Agree not to participate in another clinical trial/study or to participate in an investigational drug study for at least one month after the last procedure day
12. Agrees not to donate blood to a blood bank throughout participation in the study and for at least three months after last procedure day
13. Have a normal ECG; must not have the following to be acceptable: pathologic Q wave abnormalities, significant ST-T wave changes, left ventricular hypertrophy, right bundle branch block, left bundle branch block. (sinus rhythm is between 55-100 beats per minute)

14. Have normal vital signs:

    • Temperature 35-37.9°C (95-100.3°F)
    • Systolic blood pressure 90-140 mmHg
    • Diastolic blood pressure 60-90 mmHg
    • Heart rate 55-100 beats per minute
    • Respiration rate 12-20 breaths per minute

Exclusion Criteria:

1. Smokers/tobacco users (current use or use over the previous 2 months of nicotine-containing substances, including tobacco products (e.g., cigarettes, cigars, chewing tobacco, snuff, gum, patches, or electronic cigarettes)
2. Participation in any ongoing clinical drug trial/study
3. Hereditary skin disorders or any skin inflammatory conditions as reported by the volunteer or evident to the MAI
4. History of significant dermatologic cancers (e.g., melanoma, squamous cell carcinoma) except basal cell carcinomas that were superficial and did not involve the investigative sites
5. History as either reported by the volunteer or evident to the investigator of infectious disease or skin infection or of chronic skin disease (e.g., psoriasis, atopic dermatitis)
6. Use of medications/alternative treatments/natural products for menopausal symptoms within the last 30 days or during the study.
7. Use of some chronic prescription medications during the period 0 to 30 days; or over-the-counter medications (e.g. antihistamines, topical corticosteroids, creams, gels, or ointments on your legs) and short term (<30 days) prescription medications during the period 0-3 days before a procedure day vitamin and herbal supplements not included). Certain types of medications may not exclude volunteers from this study, for example; thyroid medications, allergy medication that is not a steroid, non-steroidal anti-inflammatory drugs (e.g., ibuprofen or naproxen), and lipid/cholesterol lowering drugs.
8. Active positive Hepatitis B, C and/or HIV serologies
9. Positive urine drug screening test
10. Use of estrogen-containing implants, topical, or oral products
11. Donation or loss of greater than one pint of blood within 60 days of entry to the study
12. Any prior allergies to estradiol and its products or other ingredients in the applied gel or cream
13. Received an experimental agent (vaccine, drug, biologic, device, blood product or medication) within one month before enrollment in this study or expects to receive an experimental agent during the study
14. Any condition that would, in the opinion of the Medically Accountable Investigator (MAI), place the volunteer at an unacceptable risk of injury or render the volunteer unable to meet the requirements of the protocol
15. History of diabetes
16. Breast cancer or history of breast cancer
17. Undiagnosed abnormal genital bleeding
18. Estrogen-dependent neoplasia (tumor)
19. Active arterial thromboembolic disease (example, stroke or heart attack), or a history of these conditions
20. Active DVT (blood clots in deep vein such as lower leg, thigh, pelvis or can occur in arm), PE (blood clot in blood vessel; often leg), or history of these conditions
21. Hepatic (liver) impairment or disease
22. Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders (tendency to form blood clots)
23. At application site, volunteer has an obvious difference in skin color between thighs, presence of a skin condition, excessive hair, sunburn, raised moles and scars, open sores, scar tissue, tattoo, or coloration that would interfere with placement of products, skin assessment, or reactions to estradiol
24. BMI ≥30 kg/m2

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Non-Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: EstroGel® 0.06%; EstroGel® 0.06% (1.25 g of gel/dose)	Drug: Estrogel 0.06 % Topical Gel; estradiol topical products; Other Names: estradiol gel
Active Comparator: Compounded estradiol product; Compounded estradiol product (equivalent to EstroGel®/dose)	Drug: Compounded estradiol gel; estradiol topical products; Other Names: estradiol gel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PK	serum concentrations	-1 through 12 hours for four consecutive days

Collaborators and Investigators

• Sponsor: University of Maryland, Baltimore
• Investigators: Principal Investigator: Audra Stinchcomb, PhD, University of Maryland, Baltimore

Study record dates

Study Major Dates

• Study Start (Estimated): May 15, 2024
• Primary Completion (Estimated): October 1, 2024
• Study Completion (Estimated): October 1, 2024

Study Registration Dates

• First Submitted: December 1, 2022
• First Submitted That Met QC Criteria: December 1, 2022
• First Posted (Actual): December 9, 2022

Study Record Updates

• Last Update Posted (Actual): April 25, 2024
• Last Update Submitted That Met QC Criteria: April 23, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Estrogens; Contraceptive Agents, Hormonal; Contraceptive Agents; Reproductive Control Agents; Contraceptive Agents, Female; Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Polyestradiol phosphate
• Other Study ID Numbers: HP-00100540

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Study results will be shared via a published manuscript.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes